


## Mavatrep

<b>Cat. No.:</b>	HY-16935		
<b>CAS No.:</b>	956274-94-5		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>21</sub> F <sub>3</sub> N <sub>2</sub> O		
<b>Molecular Weight:</b>	422.44		
<b>Target:</b>	TRP Channel		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 28 mg/mL (66.28 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3672 mL	11.8360 mL	23.6720 mL
5 mM	0.4734 mL	2.3672 mL	4.7344 mL
10 mM	0.2367 mL	1.1836 mL	2.3672 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: 2.5 mg/mL (5.92 mM); Suspended solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Mavatrep is an orally bioavailable TRPV1 antagonist (K<sub>i</sub>=6.5 nM), exhibits minimal effect on the enzymatic activity (IC<sub>50</sub> > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6. IC<sub>50</sub> value: 6.5 nM (K<sub>i</sub>, for TRPV1) Target: TRPV1 in vitro: Mavatrep exhibits superior pharmacodynamic properties. In a TRPV1 functional assay, using cells expressing recombinant human TRPV1 channels, Mavatrep antagonizes capsaicin-induced Ca<sup>2+</sup> influx, with an IC<sub>50</sub> value of 4.6 nM. Mavatrep blocks the activation of hTRPV1 channels by Capsaicin (1 μM) and by pH (5.0) in a concentration-dependent fashion, with IC<sub>50</sub> values of 23 and 6.8 nM, respectively. in vivo: Mavatrep exhibits superior pharmacodynamic properties in the CFA model of inflammatory pain.

---

## REFERENCES

---

[1]. Parsons WH, et al. Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl)-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-3874.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA